Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Debrisoquine 4-hydroxylation and sulphamethazine N-acetylation in patients with schizophrenia and major depression.

British journal of clinical pharmacology - 1 May 1996

Hadasová E, Franke G, Zschiesche M, Cesková E, Zelenková O, Siegmund W

Abstract excerpt

Debrisoquine 4-hydroxylation and sulphamethazine N-acetylation phenotypes were determined in 115 Czech drug-free in-patients with schizophrenia (n = 64) or major depressive disorder (n = 51). These data were compared with a control group of 321 healthy volunteers from the North-East German area of Greifswald. The distribution of debrisoquine hydroxylator phenotypes was almost identical in patients and healthy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme System

Share to Germany

Share to Mixed Function Oxygenases

Share to Phenotype

Share to Schizophrenia

Source

Open in PubMed Open full text

Identifiers

PMID: 8735687
DOI: 10.1046/j.1365-2125.1996.33513.x
PMCID: PMC2042602

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Debrisoquine 4-hydroxylation and sulphamethazine N-acetylation in patients with schizophrenia and major depression.PMID 8735687Read ↗

N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.Semantic proximity Read ↗

Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.Semantic proximity Read ↗

Debrisoquine oxidation phenotype during neuroleptic monotherapy.Semantic proximity Read ↗

[Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].Semantic proximity Read ↗

Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population.Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Oxidation phenotyping with debrisoquine in Germany (East).Semantic proximity Read ↗

Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.Semantic proximity Read ↗

Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.Semantic proximity Read ↗

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.Semantic proximity Read ↗

Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.